Research Article
[Retracted] Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C
Table 3
Distribution of patients with normal AHBV-DNA levels <500 copies/mL at different time periods.
| Indicators (months) | Control group (n = 26) | Tenofovir group (n = 26) | Entecavir group (n = 26) |
| 3 | 5 (20.08%) | 13 (50.19%)#& | 10 (40.15%)# | 6 | 9 (33.47%)∗ | 17 (66.92%)∗#& | 15 (56.88%)∗# | 12 | 10 (40.15%)∗@ | 20 (76.96%)∗@#& | 17 (66.92%)∗@# |
|
|